Information Provided By:
Fly News Breaks for October 17, 2016
EXAS
Oct 17, 2016 | 07:31 EDT
Canaccord analyst Mark Massaro believes Exact Sciences (EXAS) will be able to achieve its guidance when it reports Q3 results later this month. The analyst cited the company's latest coverage approval for Cologuard with Cigna (CI) and expectations for ongoing commercial momentum in the second half of the year. Massaro also feels Exact's upcoming data on its blood-based detection and /or recurring monitoring will be positive for the stock. Massaro reiterated his Buy rating and $24 price target on Exact Sciences shares.
News For EXAS From the Last 2 Days
There are no results for your query EXAS
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.